Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025

1.1 Overview
1.2 Historical Development of Tumor Infiltrating Lymphocytes Therapy

3.1 Current Application of TIL Therapy in Melanoma
3.2 TIL Beyond Monotherapy in Late Stage Melanoma
3.2.1 TIL as Combinational Therapy
3.2.2 TIL as Adjuvant Therapy
3.3 Recent Research & Advancements

4.1 Role of TIL in Colorectal Cancer
4.2 Ongoing Development

5.1 TIL in Gastric Cancer
5.2 Pancreatic Cancer
5.3 Hepatocellular Carcinoma (Liver Cancer)

6.1 TIL as Prognostic Parameter for Lung Cancer
6.2 TIL for Targeting NSCLC - Current Scenario

7.1 Impact of TIL in Ovarian Cancer
7.1.1 Therapeutic & Prognostic Potential Against Ovarian Cancer
7.1.2 Ongoing Development
7.2 Uterine/Endometrial Cancer
7.3 Cervical Cancer

8.1 Bladder/Urothelial Carcinoma
8.1.1 Applications of TILs in Urothelial Carcinoma
8.1.2 Ongoing Development
8.2 Renal Cell Carcinoma (RCC)
8.3 Prostate Cancer

9.1 Impact of TILs in Head & Neck Cancer
9.2 Ongoing Research & Advancements

10.1 Role of TIL in Glioma & Meningioma
10.2 Recent Advancements for Targeting Brain Cancer

11.1 TIL as Breast Cancer Therapeutics
11.2 Ongoing Development

13.1 Phase-I
13.2 Phase-II

14.1 Growing Frontier for Tumor Infiltrating Lymphocyte Therapy Market as Personalized Treatment
14.2 Current Market Scenario
14.3 Therapy Cost Analysis

15.1 Harnessing the Immune System with the help of Tumor-Infiltrating Lymphocytes
15.2 Tumor-Infiltrating Lymphocytes & IL-18 Acting as Promising Novel Cancer Therapies
15.3 Lovance Biotherapeutics Presentation for Tumor Infiltrating Lymphocyte Clinical Data
15.4 MacroGenics Clinical Data for Presentation for MGD019 for Advanced Solid Tumor
15.5 TILT Biotherapeutics Announces TILT-123 Trial for Tumor Infiltrating Lymphocyte Therapy on Patients
15.6 Personalized Cell Therapy Development using Tumor-Infiltrating Lymphocytes by Neogene Therapeutics
15.7 Immunosuppressive Tumor-Infiltrating T Regulatory (TITR) Cells to be the Next Target for Gilead
15.8 Lovance & Genocea to Collaborate for Developing Neoantigen Targeted Tumor-Infiltrating Lymphocytes Products
15.9 Orgenesis & Israel Public Hospital to Work Together for Expanding Tumor-Infiltrating Lymphocytes
15.10 Lovance Biotherapeutics & Cellectis to Collaborate for Developing Tumor Infiltrating Lymphocyte Products for Cancer Patients
15.11 Cellular Biomedicine & National Cancer Institute Collaboration for the Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology against Solid Tumors
15.12 Lovance Biotherapeutics to Collaborate with WuXi to Advance the Tumor Infiltrating Lymphocyte Therapies TIL-01 & TIL-04
15.13 Lonza & Coccon to Drive Autologous Cell Therapy Protocols for Tumor-Infiltrating Lymphocytes (TILs) & Mesenchymal Stem Cells (MSCs)
15.14 Lovance Therapeutics & Lytix Biopharma Collaboration for Developing Novel Tumor-Infiltrating Lymphocytes
15.15 Phase II Clinical Study for Tumor-Infiltrating Lymphocytes in Case of Metastatic Melanoma & Lung Cancer
15.16 Tumor Infiltrating Lymphocyte Therapy Boosted with Interleukin-2 Introduction
15.17 University of Pittsburgh Clinical Trial for Tumor Infiltrating Lymphocyte for Biliary Tract Cancer
15.18 Yale University Researchers to Study Tumor-Infiltrating Lymphocytes for Triple Negative Breast Cancer
15.19 Tumor Infiltrating Lymphocyte Therapy Phase Trial for Patients with Platinum Resistant Ovarian Cancer
15.20 Lion Biotechnologies & PolyBioCept AB/ Karolinska University Hospital to Collaborate for Tumor-Infiltration Lymphocyte Therapy Market Expansion & Selection for Multiple Cancer Indications

16.1 Drivers Boosting the Overall Tumor Infiltrating Lymphocyte Therapy Market Growth
16.2 Challenges Concerning the Market Growth for Tumor Infiltrating Lymphocyte Therapy

18.1 Iovance Biotherapeutics
18.2 Optera Therapeutics
18.3 TILT Therapeutics

Figure 1-1: Procedure of Tumor Infiltrating Lymphocytes Therapy
Figure 1-2: Evolution of Tumor Infiltrating Lymphocytes (TIL) Therapy
Figure 2-1: Role of Tumor Infiltrating Lymphocytes (TIL) in Cancer
Figure 2-2: Approach for Tumor Infiltrating Lymphocytes Evaluation in Solid Tumors
Figure 3-1: US – Lifileucel & LN-145 Orphan Drug Designation Year
Figure 3-2: Therapies Used in Combination with Tumor Infiltrating Lymphocytes Therapy
Figure 3-3: Tumor Infiltrating Lymphocytes as Adjuvant Therapy of Melanoma
Figure 3-4: C-144-01 Trial - Study Initiation & Expected Completion Year
Figure 4-1: Role of Tumor Infiltrating Lymphocytes in Colorectal Cancer
Figure 4-2: MDA-TIL Trial - Study Initiation & Expected Completion Year
Figure 5-1: Global – Number of Newly Diagnosed Cases of Leading Gastrointestinal Cancer, 2020
Figure 5-2: Global – Number of Deaths by Leading Gastrointestinal Cancer, 2020
Figure 5-3: Role of Tumor Infiltrating Lymphocytes in GI Cancers
Figure 5-4: Type of Infiltrated T-Cells in Lung Cancer
Figure 5-5: Infiltrated T-Cells Assisting the Prognosis of Liver Cancer
Figure 6-1: Tumor Infiltrating Lymphocytes Treatment for Lung Cancer
Figure 6-2: Type of Infiltrated T-Cells in Lung Cancer
Figure 7-1: Global – Number of Newly Diagnosed Cases of Leading Gynecological Cancer, 2020
Figure 7-2: Global – Number of Deaths by Leading Gynecological Cancer, 2020
Figure 7-3: Role of Tumor Infiltrating Lymphocytes in Various Gynecological Cancer
Figure 7-4: TILs Treatment for Ovarian Cancer
Figure 7-5: Type of Infiltrated T-Cells for Prognosis of Ovarian Cancer
Figure 7-6: OVSTAR TIL Trial: Study Initiation & Expected Completion Year
Figure 7-7: Ovarian Cancer Targeting Tumor Infiltrating Lymphocytes Therapies in Clinical Trials
Figure 8-1: Global – Number of Newly Diagnosed Cases of Leading Genitourinary Cancer, 2020
Figure 8-2: Global – Number of Deaths by Leading Genitourinary Cancer, 2020
Figure 8-3: Infiltrated T-cells in Urothelial Cancer
Figure 8-4: Infiltrated T-Cells in Renal Cell Carcinoma
Figure 8-5: Tumor Infiltrating Lymphocytes  Therapy Procedure for Prostate Cancer
Figure 8-6: T-cells Infiltrated in Prostate Cancer
Figure 9-1: Global – Newly Diagnosed Cases & Deaths related to Head & Neck Cancer, 2020
Figure 9-2: Tumor Infiltrating Lymphocytes Therapy Procedure for Targeting Head & Neck Cancer
Figure 9-3: C-145-03 Trial - Study Initiation & Expected Completion Year
Figure 10-1: Global – Newly Diagnosed Cases & Deaths related to Brain Cancer, 2020
Figure 10-2: Role of Tumor Infiltrating Lymphocytes Therapy in Brain Tumor
Figure 10-3: Infiltrated T-Cells in Brain Tumor
Figure 11-1: Global – Newly Diagnosed Cases & Deaths related to Breast Cancer (Million), 2020
Figure 11-2: Tumor Infiltrating Lymphocytes Therapy Procedure for Breast Cancer
Figure 11-3: Evaluation of TILs for Breast Cancer
Figure 11-4: LN-145 Breast Cancer Trial – Study Initiation & Expected Completion Year
Figure 12-1: Global – Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
Figure 12-2: Global – Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
Figure 12-3: Tumor Infiltrating Lymphocytes Therapy Procedure in Leukemia
Figure 12-4: Type of Beneficial Infiltrating Cells in Leukemia
Figure 12-5: Type of Beneficial Infiltrating Cells in Lymphoma
Figure 13-1: Tumor Infiltrating Lymphocytes Clinical Pipeline by Phase (%), 2020
Figure 14-1: US – Minimum & Maximum Cost of Tumor Infiltrating Lymphocytes Therapy Treatment, October’2020
Figure 14-2: Proleukin – Cost of Single Powder for Injection, Single Day & Full Treatment (US$), October’2020
Figure 14-3: Cyclophosphamide – Cost of various Supplies of Powder for Injection (US$), October’2020
Figure 14-4: Cyclophosphamide – Price of 2.5ml Supply & Price per ml of Intravenous Solution (US$), October’2020
Figure 14-5: Cyclophosphamide – Average Cost of Single Day & Full Treatment (US$), October’2020
Figure 14-6: Fludarabine – Average Cost of Single Day & Full Treatment (US$), October’2020
Figure 16-1: Driving Forces for Tumor Infiltrating Therapy Market
Figure 17-1: Global - Future Drivers for Tumor Infiltrating Lymphocyte Therapy Market
Figure 17-2: Global – Future Regional Powers for Tumor Infiltrating Lymphocyte Therapy Market